Astra, Forest to start Phase 3 superbug drug study
CAZ-AVI combines a broad-spectrum cephalosporin antibiotic
and a novel beta-lactamase inhibitor to overcome
antibiotic-resistance and treat the increasing number of
infections resistant to existing therapies.A series of five Phase III studies will test the product in
hospitalised patients with serious Gram-negative bacterial
infections in the abdomen and urinary tract.Forest will have rights to commercialise CAZ-AVI in North
America while AstraZeneca will sell it elsewhere. Both companies
will share development costs.